Shares of Aratana Therapeutics Inc (NASDAQ:PETX) were down 26.6% during mid-day trading on Friday . The company traded as low as $4.11 and last traded at $4.37. Approximately 6,797,889 shares changed hands during mid-day trading, an increase of 411% from the average daily volume of 1,329,749 shares. The stock had previously closed at $5.95.
A number of analysts have issued reports on PETX shares. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Wednesday, January 2nd. BidaskClub lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 22nd. Stifel Nicolaus lowered Aratana Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $8.00 to $5.00 in a research note on Friday. Finally, HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $7.50.
The company has a market cap of $296.12 million, a price-to-earnings ratio of -4.51 and a beta of 1.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. Research analysts predict that Aratana Therapeutics Inc will post -0.25 EPS for the current year.
In other news, insider Ernst Heinen sold 19,308 shares of Aratana Therapeutics stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total value of $134,190.60. Following the transaction, the insider now directly owns 135,694 shares of the company’s stock, valued at approximately $943,073.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Peter Steven St sold 11,513 shares of Aratana Therapeutics stock in a transaction dated Tuesday, October 30th. The shares were sold at an average price of $5.86, for a total value of $67,466.18. Following the completion of the transaction, the insider now directly owns 562,720 shares in the company, valued at $3,297,539.20. The disclosure for this sale can be found here. Insiders sold a total of 77,607 shares of company stock worth $476,116 over the last ninety days. Corporate insiders own 5.30% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hollencrest Capital Management acquired a new position in shares of Aratana Therapeutics in the 4th quarter valued at about $153,000. MetLife Investment Advisors LLC acquired a new position in Aratana Therapeutics during the 3rd quarter worth approximately $215,000. Bank of Montreal Can lifted its position in Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 31,053 shares in the last quarter. Acadian Asset Management LLC lifted its position in Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock worth $1,137,000 after acquiring an additional 80,064 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Aratana Therapeutics by 7.2% during the 2nd quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock worth $2,082,000 after acquiring an additional 32,773 shares in the last quarter. 67.92% of the stock is currently owned by institutional investors and hedge funds.
Aratana Therapeutics Company Profile (NASDAQ:PETX)
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
See Also: How is a Moving Average Calculated?
Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.